Intriguingly, we were particularly interested in the survival probabilities of patients carrying LRP1B mutations (approximately 26.7% of STAD patients carried LRP1B mutations) (HR = 3.78 × 10− 8, p-value = 0.0361) and AHNAK2 mutations (approximately 16.7% of STAD patients carried AHNAK2 mutations) (HR = 3.86 × 10− 8, p-value = 0.0493). This evidence concerns the gene AHNAK2 and gastric adenocarcinoma.